medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (2)

Identification of anti-HLA antibodies in patients awaiting renal transplant

Marcell RL, Morera BLM, Ustariz GCR, Costales EDT, Chang MA, Bencomo HA

Language: Spanish
References: 16
Page: 138-149
PDF size: 128.87 Kb.


ABSTRACT

Introduction: for patients listed in the National Renal Transplant Program it is necessary to determine the existence of anti-HLA class I and II antibodies. In case of existence, the specificity and percentage of reactivity against a cell panel must be identified (PRA).
Objective: to analyze the first cases studied by ELISA technique in order to evaluate anti-HLA sensitivity.
Methods: during 2013 and using enzime linked immunoabsorbent assays (ELISA), 866 patients were tested for anti-HLA classes I y II antibodies, and 52 positive patients were test by PRA (ELISA) to determine percentage of sensitivity and more frequent anti-HLA class I and II antibody specificities.
Results: fifty one percent presented anti-HLA antibodies and 90% of them had anti-HLA class I antibodies. All women to whom PRA was performed had sensitivity over 20% due to pregnancies and transfusions. In men the main cause of sensitivity was transfusion. The anti-HLA antibody specificities were more frequent against HLA-DR and HLA-B. Anti-HLA class I antibodies specificity were those of CREG public antigen group.
Conclusions: the principal causes of sensitivity in our population must be analyzed in order to diminish them. It is essential to secure the highest donor-receptor compatibility to increase the survival of both receptors and graft.


REFERENCES

  1. Ercilla MG, Martorell J. Estudio inmunológico de la pareja donante-receptor. Nefrologia. 2010; 30(Suppl. 2):60-70.doi: 10.3265/Nefrologia.pre2010.Nov.10692.

  2. de Leo Cervantes C. Histocompatibility tests in a transplantation program. Rev Invest Clin. 2005 Mar-Apr;57(2):142-6.

  3. Aguado García JM, Crespo Barrio M, Morales Cerdán JM. Rechazo agudo celular y rechazo agudo humoral. En: Arias M, Campisto l JM, Morales JM (editores). Manual de Trasplante renal. 2nd ed. Madrid: Pfizer; 2011. p. 111-26.

  4. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, ClaasFHJ, et al. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation. 2013 Jan 15;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.

  5. Ruiz San Millán J, Arias Rodríguez M, López Hoyos M, Pastor Martínez J. Inmunobiología del trasplante. Estudios inmunológicos del donante y receptor del trasplante renal. En: Lorenzo-Sellarés V, López-Gómez JM, editors. Nefrología al día [Internet]. 2 ed. Barcelona (Spain): Sociedad Española de Nefrología/Plusmedical; 04/12/2012 [cited 2014 Oct 24]. Disponible en: http://dx.doi.org/10.3265/Nefrologia.2010.pub1.ed80.chapter2837.

  6. Brito García A, Gutiérrez García F, Trujillo Álvarez Y, Peña Fresneda N, Barberia Torres D, Díaz Báez N. Anticuerpos anti-HLA en pacientes con insuficiencia renal crónica en espera de trasplante renal. Rev Cubana Hematol Inmunol Hemoter. 2012;28(3):275-81.

  7. Toledo R, Alvarez I, Bengochea M. Análisis de anticuerpos Anti HLA en 7 poblaciones de insuficientes renales crónicos en lista de espera para trasplante renal. Rev Urug Patol Clín. 2002;34:13-21.

  8. Valenzuela NM, Reed EF. Antibodies in Transplantation: The Effects of HLA and Non- HLA Antibody Binding and Mechanisms of Injury. In: Valenzuela NM, Reed EF.Transplantation Immunology. Methods and Protocols. 2nd ed. New York: Human Press; 2013. p. 41-70.

  9. Tinckam K. Histocompatibility methods. Transplant Rev (Orlando). 2009 Apr;23(2):80-93. doi: 10.1016/j.trre.2009.01.001.

  10. British Society for Histocompatibility & Immunogenetics, British Transplantation Society. Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. 2012. (citado Abril 25, 2014). Disponible en: http://www.bts.org.uk/Documents/Guidelines/Active/A6.pdf

  11. Fidler SJ, Irish AB, Lim W, Ferrari P, Witt CS, Christiansen FT. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transpl Immunol. 2013 Jun;28(4):148-53.

  12. Alfonso Valdés ME, Muñíz E, Bencomo Hernández A, López de Roux MR, Cruz Tamayo F, Morera Barios LM. et al . Aloanticuerpos contra células sanguíneas en embarazadas nulíparas antes y después de abortos provocados. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2008 Ago [citado 2014 Sep 12]; 24(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892008000200007&lng=es.

  13. Figueroa P. Manejo y Método del Estudio del Paciente Sensibilizado.Medwave 2001 Jul;1(07):e3433 doi: 10.5867/medwave.2001.07.3433.

  14. Lair D, Coupel S, Giral M, Hourmant M, Karam G, Usal C, et al. The effect of a first kidney transplant on a subsequent transplant outcome: an experimental and clinical study. Kidney Int. 2005 Jun;67(6):2368-75.

  15. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol. 1994 Apr;39(4):272-80.

  16. Morera Barrios LM, García Ustariz RC, García García MA, Díaz Báez N, Lam Díaz RM, et al. Frecuencia fenotípica y génica de los antígenos HLA en una muestra de la población cubana. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2005 Dic [citado 2014 Sep 12]; 21(3): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892005000300005&lng=es .




2020     |     www.medigraphic.com